Skip to main content

Table 2 Progressively increasing expression of SEMA6A in subsequent metastatic lesions from three patients

From: SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

Patient

Diagnosis

Progression

% of SEMA6A+ cells

Tumor site

% of SEMA6A+ cells

Tumor site

1

60%

Back

70%

Back

2

30%

Lung

80%

Lung

3

10%

Leg

70%

Occipital fragment